


T-DM1: connect the mechanism to the clinical evidence

DESTINY-Breast03 | Previously treated HER2-positive unresectable or metastatic breast cancer



[1] KADCYLA PI, March 2026. [2] Cho et al., Nature (2003), doi:10.1038/nature01392. [3] Cortés et al., NEJM (2022), doi:10.1056/NEJMoa2115022.

[4] Hamilton et al., ESMO Breast 2026, poster 453P. Counts redrawn from the report; percentages calculated from randomized arm denominators.

Independent educational figure. Treatment decisions require the full efficacy and safety evidence; conference findings are distinguished from peer-reviewed publications.